Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

20133,390 citationsJournal Articlebronze Open Access

Authors

Alice T. Shaw · Mass General Brigham

Dong‐Wan Kim · Seoul National University Hospital

Kazuhiko Nakagawa · Kindai University

Takashi Seto · National Hospital Organization Kyushu Cancer Center

Lucio Crinò · Azienda Ospedaliera di Perugia

Myung‐Ju Ahn · Samsung Medical Center

Tommaso De Pas

Abstract

Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement. (Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.).

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Cholangiocarcinoma and Gallbladder Cancer Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 368, Issue 25, pp. 2385-2394

DOI: 10.1056/nejmoa1214886

Field-Weighted Citation Impact: 331.87